BioSpace News Archive

Cytokinetics, Incorporated announced that on October 31, 2022 it granted stock options to purchase an aggregate of 202,500 shares of common stock to 20 new employees, whose employment commenced in October 2022, as a material inducement to their employment.

Arvinas, Inc. announced that it will participate in two upcoming conferences:

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the third quarter ended September 30, 2022.

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, today reported financial results for the third quarter ended September 30, 2022 and provided an update on recent developments in its business.

LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the first patient has been dosed in the Phase 3 LIBRA clinical trial of TP-03 in Chinese patients with Demodex blepharitis.

Inspire Medical Systems, Inc. reported financial results for the quarter ended September 30, 2022.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, November 8, 2022.

TFF Pharmaceuticals, Inc. announced program updates for Voriconazole Inhaled Powder and Tacrolimus Inhaled Powder clinical programs.

Emergent BioSolutions Inc. (NYSE:EBS) announced results from a Phase 2 study evaluating the safety and immunogenicity of the company’s adjuvanted single dose chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate in prior recipients of other investigational alphavirus vaccines.

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced data from i) two separate clinical trials evaluating its RNAi therapeutic, AB-729, in a Phase 1a/1b clinical trial (AB-729-001) and in a combination Phase 2a clinical trial with a capsid inhibitor, and ii) a preclinical study of its oral PD-L1 inhibitor, AB-101.